Literature DB >> 1260337

Response and survival in advanced breast cancer after two non-cross-resistant combinations.

C Brambilla, M De Lena, A Rossi, P Valagussa, G Bonadonna.   

Abstract

A prospective study with two cytotoxic combinations (cyclophosphamide, methotrexate, and fluorouracil (CMF), and adriamycin plus vincristine (AV)) was carried out in 110 patients with advanced breast cancer. There was no significant difference between the treatment groups in the response rate after primary treatment, the median duration of response, and the median survival. In both groups responders survived for longer than non-responders. Secondary treatment after crossover for progression or relapse resulted in response rates of 35% for AV and 20% for CMF. Toxicity was mainly represented by reversible haemosuppression. These results are comparable with those obtained with other multiple-drug regimens, and combination chemotherapy alone seems to have reached a plateau in its capacity to control disseminated breast cancer.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1260337      PMCID: PMC1639498          DOI: 10.1136/bmj.1.6013.801

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  3 in total

1.  Ranking procedures for arbitrarily restricted observation.

Authors:  N Mantel
Journal:  Biometrics       Date:  1967-03       Impact factor: 2.571

2.  Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.

Authors:  S E Jones; B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

3.  Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.

Authors:  M De Lena; C Brambilla; A Morabito; G Bonadonna
Journal:  Cancer       Date:  1975-04       Impact factor: 6.860

  3 in total
  23 in total

1.  Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.

Authors:  C Manegold; P Worst; J Bickel; H Schmid; P Drings; M Kaufmann
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Review: biologic heterogeneity of cancer metastases.

Authors:  I J Fidler
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

3.  Adjuvant chemotherapy in postmenopausal women: results of sequential noncross-resistant regimens.

Authors:  C Brambilla; A Rossi; P Valagussa; G Bonadonna
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

4.  Ifosfamide combination chemotherapy in advanced breast cancer.

Authors:  H Schmid; M Kaufmann; E M Grischke; G Bastert
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C.

Authors:  W Scheithauer; G Kornek; K Haider; W Kwasny; T Schenk; R Pirker; D Depisch
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer.

Authors:  M De Lena; R Zucali; G Viganotti; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

7.  Sequential combination chemotherapy in advanced breast cancer.

Authors:  C Brambilla; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

8.  The modulating effects of flurbiprofen on adriamycin plus vincristine or vindesine in the treatment of advanced breast cancer.

Authors:  D J Perez; T J Powles; I E Smith; M D Vincent; S Ashley; C Gordon; J Gibb; S Clarke; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 9.  Update on cancer chemotherapy: general considerations and breast cancer. Part II.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-09       Impact factor: 1.798

10.  Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.

Authors:  G Bonadonna; P Valagussa; A Rossi; G Tancini; C Brambilla; M Zambetti; U Veronesi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.